Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Delarue

Showing results (71-80 of 83) with videos related to

Pageof 9
Sort By:
Gut|November 19, 2018
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC studyMorgane Cheminant, Julie Bruneau, Georgia Malamut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapyMatthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaPier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA StudySydney Dubois, Pierre-Julien Viailly, Sylvain Mareschal, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2017
ABVD or BEACOPP<sub>baseline</sub> along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trialChristophe Fermé, José Thomas, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2018
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical TrialsMatthew J Maurer, Hervé Ghesquières, Brian K Link, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP TrialVincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
Pageof 9

Showing results (71-80 of 83) with videos related to

Sort By:
Pageof 9
Gut|November 19, 2018
NKp46 is a diagnostic biomarker and may be a therapeutic target in gastrointestinal T-cell lymphoproliferative diseases: a CELAC studyMorgane Cheminant, Julie Bruneau, Georgia Malamut, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 20, 2014
Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapyMatthew J Maurer, Hervé Ghesquières, Jean-Philippe Jais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaPier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 29, 2021
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA)Emmanuel Bachy, Vincent Camus, Catherine Thieblemont, et al.
The Lancet. Oncology|January 20, 2019
PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 studyRené-Olivier Casasnovas, Reda Bouabdallah, Pauline Brice, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2016
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA StudySydney Dubois, Pierre-Julien Viailly, Sylvain Mareschal, et al.
European Journal of Cancer (Oxford, England : 1990)|June 12, 2017
ABVD or BEACOPP<sub>baseline</sub> along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trialChristophe Fermé, José Thomas, Pauline Brice, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 20, 2018
Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical TrialsMatthew J Maurer, Hervé Ghesquières, Brian K Link, et al.
Lancet (London, England)|June 18, 2016
Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma NetworkOlivier Hermine, Eva Hoster, Jan Walewski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2024
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP TrialVincent Camus, Catherine Thieblemont, Philippe Gaulard, et al.
Pageof 9